Regado Biosciences decreases price to $5 and increases shares offered

By Renaissance Capital,

Shutterstock photo

Regado Biosciences, which is developing break-through anticoagulant system for cardiovascular surgeries, lowered the proposed deal size for its upcoming IPO on Monday. The Basking Ridge, NJ-based company now plans to raise $42 million by offering 8.4 million shares at $5 per share. The company had previously filed to offer 5.0 million shares at a range of $14 to $16. At the midpoint of the revised range, Regado Biosciences would raise 44% fewer proceeds than previously anticipated.

Regado Biosciences, which was founded in 2001, plans to list on the NASDAQ under the symbol RGDO. The company initially filed confidentially on March 1, 2013. Cowen & Company and BMO Capital Markets are the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: RGDO

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by